PRESS Act
Summary
The PRESS Act (S. 4446) is an early-stage criminal enforcement bill introduced by Sen. Moody (R-FL) targeting pill press equipment used to counterfeit controlled substances for import. It amends the Controlled Substances Act to add extraterritorial jurisdiction but authorizes no new funding, appropriations, or spending. Market impact is negligible — the bill imposes compliance obligations on a narrow slice of equipment manufacturers and distributors with no direct revenue effect on publicly traded companies.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S. 4446 has zero authorized funding — it is a criminal enforcement-only bill with no government spending or contracting implications.
- 2.No publicly traded US company is directly exposed to the bill's provisions; primary targets are illicit foreign equipment suppliers.
- 3.Legislative momentum is low — single sponsor, no cosponsors beyond the introducer, referred to committee with no subsequent action in 41 days.
Market Implications
The PRESS Act has no identifiable path to affecting any publicly traded company's revenue, costs, or competitive position. It is a narrow criminal jurisdiction expansion with no funding, no procurement, and no regulatory impact on legitimate US businesses. Retail investors should ignore this bill until it advances to committee markup (unlikely in 2026 election year).
Full Analysis
-
S. 4446 (PRESS Act) was introduced in the Senate on April 30, 2026, read twice, and referred to the Judiciary Committee. It is in early procedural stages with no committee markup or floor action. The bill amends 21 U.S.C. 959 and 960 to criminalize the overseas manufacture or distribution of pill press machines, dies, encapsulating machines, and related equipment when the person intends or knows the equipment will be used to make counterfeit controlled substances for import into the US. This expands existing jurisdiction but does not establish any new spending program.
-
The money trail: Zero. The bill authorizes no appropriations. It is a criminal penalty expansion bill. No grants, tax credits, procurement programs, or subsidies are created. The only economic impact is potential compliance costs for equipment manufacturers and distributors who must verify end-use and jurisdiction.
-
Structural winners and losers: There are no structural winners. The bill targets illicit actors — Chinese and transnational pill press suppliers — not US public companies. Legitimate US pharmaceutical equipment makers (e.g., Natoli Engineering, Scheu & Kniss — privately held) and generic drug manufacturers already operate under DEA registration and federal anti-diversion rules. No publicly traded US company derives material revenue from the specific equipment covered, and no legitimate company would be affected competitively.
-
REAL MARKET DATA: None provided. No historical precedent for market reactions to isolated extraterritorial criminal provisions.
-
Timeline: The bill must pass the Senate Judiciary Committee (Chair: Sen. Grassley/Rep. Jordan depending on chamber; 119th Congress Republican majority), then receive floor time. Companion bill HR 7184 is referred to Energy & Commerce and Judiciary in the House. Early stage; less than 10% chance of enactment in current form.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
PRESS Act
Fight Illicit Pill Presses Act
Fight Illicit Pill Presses Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restoring Reciprocity in Government Procurement
This Presidential Memorandum directs the Office of Management and Budget, the U.S. Trade Representative, and other federal agencies to identify and remove Canadian-origin items from federal civil procurement where possible, citing Canada's 'Buy Canadian' policies as discriminatory. It also requires agencies to be notified of domestic alternatives and mandates ongoing monitoring of Canada's procurement practices, with provisions for restoring access if Canada changes its policies.
Excluding Certain Canadian Alcoholic Beverages from Importation into the United States in Response to Continued Discrimination Against the Commerce of the United States with Respect to Alcoholic Beverages
President Trump, invoking Section 338 of the Tariff Act of 1930, orders an import ban on certain Canadian alcoholic beverages effective September 29, 2026, escalating previous 50% ad valorem duties. This action targets Canadian discrimination against U.S. alcoholic beverages, citing Canada's broken commitments and additional retaliation. The ban replaces the tariff for specified products with a complete exclusion from entry into the United States.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →